Accelerated Approval Requests Based On Low Efficacy Frustrate FDA
Executive Summary
FDA appears to be increasingly frustrated with sponsors who seek accelerated approval based upon the lowest possible efficacy standard
You may also be interested in...
Iressa Gets Narrowed Indication Instead Of Withdrawal: New Model For FDA?
FDA's decision to narrow the indication for AstraZeneca's Iressa rather than withdraw the drug could be seen as a model for future products approved under Subpart H that fail in confirmatory trials
Iressa Gets Narrowed Indication Instead Of Withdrawal: New Model For FDA?
FDA's decision to narrow the indication for AstraZeneca's Iressa rather than withdraw the drug could be seen as a model for future products approved under Subpart H that fail in confirmatory trials
Iressa Committee Will Not Vote On Market Withdrawal; FDA To Review Data
FDA's Oncologic Drugs Advisory Committee will not vote on whether the lung cancer therapy Iressa should be removed from the market during its March 4 meeting, AstraZeneca said